Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
UCB SA, Medical Devices Deals, 2011 to YTD 2017 13
UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
UCB SA, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 18
UCB Acquires Key Assets Of Lectus Therapeutics 19
Venture Financing 20
Lumos Pharma Raises USD34 Million in Series B Financing Round 20
Clementia Pharma Secures USD60 Million Venture Financing 22
Clementia Pharma Raises USD60 Million in Venture Financing 24
Dermira Raises USD51 Million In Series C Venture Financing 26
Partnerships 28
Q-State Biosciences Enters into Research Agreement with UCB 28
NovAliX Enters into Agreement with UCB Biopharma 29
MC10 Enters into Agreement with UCB 30
MRC Technology, UCB and University of Leicester Enter into Agreement 31
UCB Enters into Research Agreement with Baylor College of Medicine 32
Evotec Partners with UCB 33
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 34
Beryllium Enters into Agreement with UCB to Develop Drug Targets 35
Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 36
Sanofi Enters Into Agreement With UCB For Drug Discovery 37
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 38
Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 39
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 40
UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 41
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 42
UCB Enters Into Research Agreement With Five Prime Therapeutics 43
ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 44
biOasis Technologies Enters Into Research Agreement With UCB 45
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 46
UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 47
UCB Enters Into Co-Development Agreement With Harvard University 48
UCB Enters Into Co-Development Agreement With Imperial College London 49
UCB Enters Into Co-Development Agreement With Oxford University 50
Nodality Enters Into Co-Developement Agreement With UCB Pharma 51
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 52
Otsuka Pharma Amends Co-Development Agreement With UCB 54
Emerald BioStructures Extends Co-Development Agreement With UCB 56
Evotec Enters Into Co-Development Agreement With UCB 57
Evotec Enters Into Drug Discovery Collaboration With UCB 58
UCB Enters Into Research Agreement With TechnoPhage 59
UCB Enters Into Research Collaboration With Katholieke Universiteit Leuven 60
Hurel Enters Into Co-Development Agreement With UCB Pharma 61
UCB Enters Into Co-Development Agreement With Harvard University 62
Emerald BioStructures Extends Co-Development Agreement With UCB 63
Licensing Agreements 64
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64
King’s College London Enters Into Licensing Agreement with UCB 65
UCB to Terminate Licensing Agreement with Dermira for Cimzia 66
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 68
Zai Lab Enters into Licensing Agreement with UCB 69
UCB Exercises Option for Licensing Agreement with Oncodesign 70
King’s College Enters into Licensing Agreement with UCB 71
Neuropore Therapies Enters into Licensing Agreement with UCB 72
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 73
ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 74
Equity Offering 75
Dermira Raises USD7.5 Million in Private Placement of Shares 75
Wilex Completes Private Placement Of Shares For US$12.4 Million 77
Debt Offering 78
UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78
UCB Completes Private Placement Of 4.125% Bonds Due 2021 For US$473.2 Million 79
UCB Completes Public Offering Of Bonds For US$326 Million 80
UCB Completes Private Placement Of Perpetual Subordinated Bonds For US$419.5 Million 81
Asset Transactions 82
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 82
Dr Reddy’s Labs Acquires Brands Portfolio of UCB for USD128 Million 83
Exemed Pharma Acquires Indian Production Facility of UCB 84
Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 85
Unither Pharma Acquires Pharma Manufacturing Plant from UCB 86
Aesica Pharma Acquires Three Manufacturing Sites From UCB 87
Acquisition 89
UCB Pharma Acquires Remaining Stake in Beryllium Discovery 89
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90
UCB Acquires 51% Stake In Meizler Biopharma 92
Biotie Therapies Acquires Synosia Therapeutics 93
UCB SA – Key Competitors 96
UCB SA – Key Employees 97
UCB SA – Locations And Subsidiaries 98
Head Office 98
Other Locations & Subsidiaries 98
Joint Venture 101
Recent Developments 102
Financial Announcements 102
Oct 20, 2017: UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook 102
Jul 27, 2017: UCB with a strong first half year 2017 – giving rise to the financial outlook for 2017 104
Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 107
Jul 27, 2016: UCB continues to deliver on its growth strategy 108
Apr 25, 2016: UCB First Three Months Interim Report 2016 109
Feb 26, 2016: UCB with progress on its growth path delivering value to patients and shareholders 110
Corporate Communications 112
Mar 24, 2017: UCB General Meeting on 27 April 2017 112
Dec 15, 2016: New appointments on UCB’s Board of Directors 113
Mar 25, 2016: Nominations for new members of UCB’s Board of Directors 114
Government and Public Interest 115
Feb 01, 2016: ConfometRx unlocks novel GPCR-G protein structure within UCB research collaboration 115
Product News 116
12/02/2016: UCB highlights data on VIMPAT (lacosamide) CV at the 2016 American Epilepsy Society Annual Meeting 116
09/21/2017: UCB’s anti-epileptic drug VIMPAT (lacosamide) receives EU approval for paediatric use 118
08/31/2016: Antiepileptic Drug Vimpat Tablets 50mg and 100mg have been launched 119
08/25/2017: Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients 120
07/20/2017: UCB Pharma Receives CHMP Positive Opinion for Vimpat 121
07/04/2016: UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy 122
Product Approvals 123
Sep 01, 2017: Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg 123
Mar 13, 2017: UCB Pharmas Vimpat Rejects For Use Within NHS Scotland 124
Nov 11, 2016: UCBs anti-epileptic drug VIMPAT (lacosamide) receives positive opinion by EU CHMP as monotherapy for patients with partial-onset seizures 125
Aug 26, 2016: Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan 126
Clinical Trials 127
Jun 10, 2016: UCB’s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis 127
Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016) 128
Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016) 129
May 30, 2016: Positive VIMPAT (lacosamide) monotherapy Phase III trial results presented at European Academy of Neurology Congress 130
Appendix 131
Methodology 131
About GlobalData 131
Contact Us 131
Disclaimer 131
UCB SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
UCB SA, Deals By Therapy Area, 2011 to YTD 2017 11
UCB SA, Medical Devices Deals, 2011 to YTD 2017 13
UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 18
UCB Acquires Key Assets Of Lectus Therapeutics 19
Lumos Pharma Raises USD34 Million in Series B Financing Round 20
Clementia Pharma Secures USD60 Million Venture Financing 22
Clementia Pharma Raises USD60 Million in Venture Financing 24
Dermira Raises USD51 Million In Series C Venture Financing 26
Q-State Biosciences Enters into Research Agreement with UCB 28
NovAliX Enters into Agreement with UCB Biopharma 29
MC10 Enters into Agreement with UCB 30
MRC Technology, UCB and University of Leicester Enter into Agreement 31
UCB Enters into Research Agreement with Baylor College of Medicine 32
Evotec Partners with UCB 33
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 34
Beryllium Enters into Agreement with UCB to Develop Drug Targets 35
Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 36
Sanofi Enters Into Agreement With UCB For Drug Discovery 37
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 38
Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 39
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 40
UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 41
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 42
UCB Enters Into Research Agreement With Five Prime Therapeutics 43
ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 44
biOasis Technologies Enters Into Research Agreement With UCB 45
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 46
UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 47
UCB Enters Into Co-Development Agreement With Harvard University 48
UCB Enters Into Co-Development Agreement With Imperial College London 49
UCB Enters Into Co-Development Agreement With Oxford University 50
Nodality Enters Into Co-Developement Agreement With UCB Pharma 51
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 52
Otsuka Pharma Amends Co-Development Agreement With UCB 54
Emerald BioStructures Extends Co-Development Agreement With UCB 56
Evotec Enters Into Co-Development Agreement With UCB 57
Evotec Enters Into Drug Discovery Collaboration With UCB 58
UCB Enters Into Research Agreement With TechnoPhage 59
UCB Enters Into Research Collaboration With Katholieke Universiteit Leuven 60
Hurel Enters Into Co-Development Agreement With UCB Pharma 61
UCB Enters Into Co-Development Agreement With Harvard University 62
Emerald BioStructures Extends Co-Development Agreement With UCB 63
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64
King’s College London Enters Into Licensing Agreement with UCB 65
UCB to Terminate Licensing Agreement with Dermira for Cimzia 66
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 68
Zai Lab Enters into Licensing Agreement with UCB 69
UCB Exercises Option for Licensing Agreement with Oncodesign 70
King's College Enters into Licensing Agreement with UCB 71
Neuropore Therapies Enters into Licensing Agreement with UCB 72
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 73
ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 74
Dermira Raises USD7.5 Million in Private Placement of Shares 75
Wilex Completes Private Placement Of Shares For US$12.4 Million 77
UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78
UCB Completes Private Placement Of 4.125% Bonds Due 2021 For US$473.2 Million 79
UCB Completes Public Offering Of Bonds For US$326 Million 80
UCB Completes Private Placement Of Perpetual Subordinated Bonds For US$419.5 Million 81
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 82
Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 83
Exemed Pharma Acquires Indian Production Facility of UCB 84
Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 85
Unither Pharma Acquires Pharma Manufacturing Plant from UCB 86
Aesica Pharma Acquires Three Manufacturing Sites From UCB 87
UCB Pharma Acquires Remaining Stake in Beryllium Discovery 89
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90
UCB Acquires 51% Stake In Meizler Biopharma 92
Biotie Therapies Acquires Synosia Therapeutics 93
UCB SA, Key Competitors 96
UCB SA, Key Employees 97
UCB SA, Subsidiaries 98
UCB SA, Joint Venture 101
